KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Non-Controlling Interests (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Income from Non-Controlling Interests data on record, last reported at $15.8 million in Q3 2025.

  • For Q3 2025, Income from Non-Controlling Interests rose 32.32% year-over-year to $15.8 million; the TTM value through Sep 2025 reached $50.4 million, up 32.82%, while the annual FY2024 figure was $43.0 million, 21.94% up from the prior year.
  • Income from Non-Controlling Interests reached $15.8 million in Q3 2025 per AMRX's latest filing, up from $12.4 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $17.8 million in Q2 2023 and bottomed at -$119.3 million in Q2 2022.
  • Average Income from Non-Controlling Interests over 5 years is -$512666.7, with a median of $8.9 million recorded in 2021.
  • Peak YoY movement for Income from Non-Controlling Interests: plummeted 776.0% in 2022, then surged 5034.11% in 2023.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$14.1 million in 2021, then surged by 89.17% to -$1.5 million in 2022, then soared by 447.87% to $5.3 million in 2023, then skyrocketed by 94.89% to $10.3 million in 2024, then soared by 52.46% to $15.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Non-Controlling Interests were $15.8 million in Q3 2025, $12.4 million in Q1 2025, and $10.3 million in Q4 2024.